Decision Maker: Director of Resources
Decision status: Recommendations Approved
Is Key decision?: No
Is subject to call in?: No
The Chief Officer Financial Services has
approved the request from Labcorp Drug Development for business
rates relief at £335,000 over a three year period from
FY21/22 and the rates relief be released incrementally over 3 years
as follows: 40% in FY 2021/22 (£134,000), 40% in 2022/23
(£134,000) and 20% in 2023/24 (£67,000).
Wards Affected: Beeston and Holbeck;
Contact: Tariq Sadiq, Inward Investment Manager 0113 378 6971 Email: email@example.com.
Publication date: 01/10/2021